NCT07107490View on ClinicalTrials.gov

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
DRUG

ALPS12

ALPS12 as an IV infusion

DRUG

obinutuzumab

Obinutuzumab as an IV infusion

Trial Locations (1)

277-8577

National Cancer Center Hospital East, Kashiwa

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY